Moisand Fitzgerald Tamayo LLC Sells 113 Shares of Johnson & Johnson $JNJ

Moisand Fitzgerald Tamayo LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,818 shares of the company’s stock after selling 113 shares during the quarter. Moisand Fitzgerald Tamayo LLC’s holdings in Johnson & Johnson were worth $736,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Nuveen LLC bought a new position in Johnson & Johnson in the 1st quarter valued at approximately $1,369,188,000. Bank of New York Mellon Corp increased its position in shares of Johnson & Johnson by 26.4% during the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock worth $3,844,580,000 after acquiring an additional 4,842,582 shares during the period. Pacer Advisors Inc. boosted its stake in Johnson & Johnson by 1,382.0% in the first quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock valued at $502,509,000 after acquiring an additional 2,825,626 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in Johnson & Johnson by 159.6% during the second quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock valued at $635,327,000 after purchasing an additional 2,557,388 shares during the period. Finally, Kingstone Capital Partners Texas LLC purchased a new position in Johnson & Johnson in the second quarter valued at $401,420,000. Institutional investors own 69.55% of the company’s stock.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $179.69 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The firm has a market cap of $432.75 billion, a price-to-earnings ratio of 19.22, a PEG ratio of 2.29 and a beta of 0.40. The business’s fifty day moving average is $174.41 and its 200 day moving average is $162.06. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $181.16.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same quarter last year, the company earned $2.82 EPS. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 55.61%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on JNJ shares. Morgan Stanley upped their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. JPMorgan Chase & Co. raised their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Tuesday, September 16th. UBS Group increased their price target on Johnson & Johnson from $180.00 to $190.00 and gave the company a “buy” rating in a report on Thursday, July 17th. Guggenheim upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Finally, Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $181.40.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.